Litcius/Paper detail

Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial

Mårten Falkenberg, Stefan James, Manne Andersson, Mattias Andersson, Martin Delle, Jan Engström, Torbjörn Fransson, Peter Gillgren, Anna Hilbertson, Tal M. Hörer, Eva Jacobsson, Björn Kragsterman, Johan Lindbäck, Hans Lindgren, Karin Ludwigs, Stefan Mellander, Olle Nelzén, Robert Olin, Birgitta Sigvant, Per Skoog, Joachim Starck, Gustaf Tegler, Knut Thorbjørnsen, Maria Truedson, Carl‐Magnus Wahlgren, Jonas Wallinder, Andreas Öjersjö, Joakim Nordanstig

2025The Lancet30 citationsDOI

Topics & Concepts

MedicinePaclitaxelRandomized controlled trialAngioplastySurgeryInternal medicineChemotherapyPeripheral Artery Disease ManagementCerebrovascular and Carotid Artery DiseasesAortic aneurysm repair treatments
Paclitaxel-coated versus uncoated devices for infrainguinal endovascular revascularisation in chronic limb-threatening ischaemia (SWEDEPAD 1): a multicentre, participant-masked, registry-based, randomised controlled trial | Litcius